2-232523817-AC-ACC
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_001195129.2(PRSS56):c.1066dupC(p.Gln356fs) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000389 in 1,530,524 control chromosomes in the GnomAD database, including 1 homozygotes. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.00040 ( 0 hom., cov: 34)
Exomes 𝑓: 0.00039 ( 1 hom. )
Consequence
PRSS56
NM_001195129.2 frameshift
NM_001195129.2 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: -1.82
Genes affected
PRSS56 (HGNC:39433): (serine protease 56) This gene encodes a protein that contains a peptidase S1 domain and possesses trypsin-like serine protease activity. The encoded protein may play a role in eye development, and mutations in this gene are a cause of autosomal recessive posterior microphthalmos. [provided by RefSeq, Dec 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 2-232523817-A-AC is Pathogenic according to our data. Variant chr2-232523817-A-AC is described in ClinVar as [Likely_pathogenic]. Clinvar id is 31077.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PRSS56 | NM_001195129.2 | c.1066dupC | p.Gln356fs | frameshift_variant | 9/13 | ENST00000617714.2 | NP_001182058.1 | |
PRSS56 | NM_001369848.1 | c.1069dupC | p.Gln357fs | frameshift_variant | 9/13 | NP_001356777.1 | ||
PRSS56 | XM_047445431.1 | c.1069dupC | p.Gln357fs | frameshift_variant | 9/12 | XP_047301387.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PRSS56 | ENST00000617714.2 | c.1066dupC | p.Gln356fs | frameshift_variant | 9/13 | 5 | NM_001195129.2 | ENSP00000479745.1 |
Frequencies
GnomAD3 genomes AF: 0.000399 AC: 60AN: 150424Hom.: 0 Cov.: 34
GnomAD3 genomes
AF:
AC:
60
AN:
150424
Hom.:
Cov.:
34
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.000388 AC: 536AN: 1379988Hom.: 1 Cov.: 35 AF XY: 0.000388 AC XY: 264AN XY: 680812
GnomAD4 exome
AF:
AC:
536
AN:
1379988
Hom.:
Cov.:
35
AF XY:
AC XY:
264
AN XY:
680812
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000399 AC: 60AN: 150536Hom.: 0 Cov.: 34 AF XY: 0.000408 AC XY: 30AN XY: 73504
GnomAD4 genome
AF:
AC:
60
AN:
150536
Hom.:
Cov.:
34
AF XY:
AC XY:
30
AN XY:
73504
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Isolated microphthalmia 6 Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Mar 29, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 11, 2021 | This sequence change creates a premature translational stop signal (p.Gln356Profs*152) in the PRSS56 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PRSS56 are known to be pathogenic (PMID: 31266062, 31992737). This variant is present in population databases (rs746758123, gnomAD 0.07%). This premature translational stop signal has been observed in individual(s) with posterior microphthalmia (PMID: 21397065, 21532570, 23127749). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 31077). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 01, 2013 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Jan 03, 2022 | The variant has been reported at least twice as pathogenic/likely pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000031077, PMID:21397065). Frameshift: predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant (PVS1_VS). It is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.000367, PM2_M). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
PRSS56-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Oct 11, 2023 | The PRSS56 c.1066dupC variant is predicted to result in a frameshift and premature protein termination (p.Gln356Profs*152). This variant has been reported as pathogenic for autosomal recessive microphthalmia (Gal et al. 2011. PubMed ID: 21397065; Prasov et al. 2020. PubMed ID: 33203948). This variant is reported in 0.069% of alleles in individuals of European (Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/2-233388527-A-AC) and is classified as pathogenic in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/31077). This variant is interpreted as pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 27, 2019 | Considered a founder mutation in the Tunisian population (Nair et al., 2011); Observed in homozygous state in multiple unrelated patients in published literature (Nowilaty et al., 2013) and not observed in homozygous state in controls; Frameshift variant in the C-terminus predicted to result in protein truncation, as the last 248 amino acids are lost and replaced with 151 incorrect amino acids; Observed in 0.0324% (10/30878 alleles) in large population cohorts (Lek et al., 2016) - |
Nanophthalmia Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Aug 08, 2019 | The p.Gln356ProfsX152 variant in PRSS56 has been reported as a homozygous variant in 7 consanguineous families with posterior microphthalmos, and as a heterozygous variant in 2 individuals with primary angle-closure glaucoma (PACG) and high hyperopia (Aldahmesh 2011, Nair 2011, Gal 2011, Nowilaty 2013, Jiang 2013). In the 7 consanguineous families, this variant segregated in the homozygous state in at least 12 additional affected relatives, and no tested unaffected relatives were homozygous (Nair 2011, Gal 2011). This variant has also been identified in 0.06% (6/8736) of Finish chromosomes by gnomAD (http://gnomad.broadinstitute.org). This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 356 and leads to a premature termination codon 152 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal recessive posterior microphthalmos. ACMG/AMP Criteria applied: PP1_Strong; PM3. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AG_spliceai
Position offset: 11
Find out detailed SpliceAI scores and Pangolin per-transcript scores at